Australians with types of vasculitis, leukaemia, heart disease, ulcerative colitis and arthritis now have access to new and ...

AstraZeneca’s supplemental New Drug Application (sNDA) for CALQUENCE® (acalabrutinib) has been accepted and granted Priority Review in the US for the treatment of adult patients with previously ...

AstraZeneca’s supplemental New Drug Application (sNDA) for CALQUENCE® (acalabrutinib) has been accepted and granted Priority Review in the US for the treatment of adult patients with previously ...

Nurix Therapeutics offers promising targeted protein degradation treatments for cancer and autoimmune diseases. Find out what ...

US FDA accepts and grants priority review status to AstraZeneca’s sNDA for Calquence to treat patients with untreated MCL: Cambridge, UK Friday, October 4, 2024, 09:00 Hrs [IST] ...

The efficacy of drugs targeting the B-cell receptor signaling pathway has invigorated the enthusiasm to molecularly identify lymphoma subcategories that offer unique therapeutic opportunities.

and for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). This information is based on a press release statement from AstraZeneca.

MCL is a rare and typically aggressive form of non-Hodgkin lymphoma (NHL), resulting when B-lymphocytes mutate into malignant cells within a region of the lymph node known as the mantle zone.